—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Recursion Pharmaceuticals Inc (RXRX) — chart, structure and Closelooknet read

The Closelooknet read

Recursion Pharmaceuticals combines robotics, cell biology and data science to run drug discovery at industrial scale rather than through traditional lab-by-lab experiments. It has several candidates in early clinical trials, aimed at rare genetic disease, solid tumours, lymphoma and blood cancers, and works with larger drug makers such as Roche, Sanofi, Bayer and Takeda on parts of this pipeline.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Research diary readings, not advice.

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for RXRX, from the same nightly bakes the boards use. Research diary readings, not advice.

Mentioned on Closelooknet 2 pieces · newest: Daily Pulse, “Pattern 03 cohort — NVIDIA equity deployments as Rubin Build-Out leading indicator” (2026-05-26)

Mentioned on Closelooknet

Where RXRX appears in the diary — 2 pieces, newest first. Every link is our own writing.

Long reads

  • Pattern 03 — NVIDIA Strategic Authority InvestmentReport · 12 May 2026The 16-Event Timeline (2023-07-12 → 2026-05-12) 2024 2025 2026 RXRX 23-07 ARM 23-09 APLD 24-09 NBIS 24-12 MRVL 25-03 CRWV 25-03 INTC 25-09 NOK 25-10 SNPS 25-12 LITE COHR 26-03 IREN 26-05 GLW 26-05 exit RXRX exit APLD exit ARM Tier 1 …

Dailies

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 46/100 · S&P 500 fund at 49, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-30
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 81th percentile of the window, -13.7% over 20 sessions. Factor regime → 2026-10-29
  • Sovereign pressure Index -1.66 · down 2.24 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-30
How it trades on rate days beta 1.65 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How RXRX has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 1.65 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Recursion Pharmaceuticals Inc moved 1.65% on average · correlation 0.22 · higher than 97% of US names
  • Beta, last 3 months 1.41 less rate-sensitive lately than over the year
  • On the 10 worst bond days −2.69% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +5.14% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against RXRX on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Recursion Pharmaceuticals Inc

RXRX in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Recursion Pharmaceuticals combines robotics, cell biology and data science to run drug discovery at industrial scale rather than through traditional lab-by-lab experiments. It has several candidates in early clinical trials, aimed at rare genetic disease, solid tumours, lymphoma and blood cancers, and works with larger drug makers such as Roche, Sanofi, Bayer and Takeda on parts of this pipeline. It is headquartered in Salt Lake City, Utah, and listed in the United States.
Where it sits in the stack
Recursion holds no seat in Closelooknet's Rubin index, the diary's map of the AI build-out. It sits instead in the broader healthcare and biotechnology sleeve of our universe, tracked as a user of AI-driven discovery tools rather than a supplier of AI infrastructure.
Who it is priced against
Closelooknet has not assigned Recursion a peer group. The competitor the market most often names alongside it is Exscientia, another company built around AI-driven drug discovery.
Why Closelooknet tracks it
Recursion carries no Closelooknet score and no index seat. It appears in the Pattern 03 report, which follows NVIDIA's strategic equity stakes as an early signal for the Rubin build-out, and in the Daily Pulse that tracks the resulting cohort; the most recent Daily Pulse shows Recursion had exited that tracked portfolio.
What the diary watches
The diary watches whether Recursion re-enters the Pattern 03 cohort if NVIDIA renews its investment, and whether clinical trial readouts from its pipeline draw attention back to the name.

Recursion Pharmaceuticals Inc (RXRX) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: price target by Morgan Stanley, 2026-10-16

The Street on this name

Analyst actions and the latest print for RXRX from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Morgan Stanley — target 5.9 from 5.3 Target raised to $5.9 from $5.3 (+56.7% to spot) 2026-10-16

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

FAQ · from the current data · as of 2026-10-31

Quick answers

What is Recursion Pharmaceuticals Inc (RXRX)?

Recursion Pharmaceuticals Inc trades as RXRX on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-10-31.

Is RXRX in a Closelooknet index?

Not currently — Recursion Pharmaceuticals Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-31.

Where does RXRX trade against its moving averages?

Recursion Pharmaceuticals Inc trades 7.6% above its 50-day and 14.3% above its 200-day moving average (0.9% above its 20-day). As of 2026-10-30 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Recursion Pharmaceuticals Inc compare with its peers?

Against its peer group (Biotechnology · US), Recursion Pharmaceuticals Inc (RXRX) sits 31.0% below its 52-week high, 7.6% above its 50-day average; Halozyme Therapeutics Inc (HALO) is 2.3% below, BeiGene, Ltd. (ONC) is 4.7% below, argenx NV ADR (ARGX) is 16.8% below, as of 2026-10-30. Put any of them next to RXRX in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Recursion Pharmaceuticals Inc trade when bond yields rise?

Over the past year Recursion Pharmaceuticals Inc had a beta of 1.65 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 97% of US names. On the 10 sessions in which long bonds fell most it moved −2.69% on average, against −0.74% for the S&P 500. As of 2026-10-30; The "How it trades on rate days" block on this page carries the lines.

Where has Closelooknet written about Recursion Pharmaceuticals Inc?

Recursion Pharmaceuticals Inc appears in 2 Closelooknet pieces as of 2026-10-31, most recently Daily Pulse: Pattern 03 cohort — NVIDIA equity deployments as Rubin Build-Out leading indicator (2026-05-26); Report: Pattern 03 — NVIDIA Strategic Authority Investment (2026-05-12). What Closelooknet said most recently: Live cohort · 10 names Current portfolio after applying the 16-event timeline through 2026-05-26: COHR · CRWV · GLW · INTC · IREN · LITE · MRVL · NBIS · NOK · SNPS Hypothetical portfolio · $100k per signal Assumes a diary follower would… (Daily Pulse, 2026-05-26). The "Mentioned on Closelooknet" block on this page lists the long reads, the reference entries and the dailies that name it.

What does Recursion Pharmaceuticals Inc do?

Recursion Pharmaceuticals combines robotics, cell biology and data science to run drug discovery at industrial scale rather than through traditional lab-by-lab experiments. It has several candidates in early clinical trials, aimed at rare genetic disease, solid tumours, lymphoma and blood cancers, and works with larger drug makers such as Roche, Sanofi, Bayer and Takeda on parts of this pipeline. It is headquartered in Salt Lake City, Utah, and listed in the United States. Closelooknet has not assigned Recursion a peer group. The competitor the market most often names alongside it is Exscientia, another company built around AI-driven drug discovery. (Company snapshot of 2026-09-17.)

Where does Recursion Pharmaceuticals Inc sit in the AI build-out?

Recursion holds no seat in Closelooknet's Rubin index, the diary's map of the AI build-out. It sits instead in the broader healthcare and biotechnology sleeve of our universe, tracked as a user of AI-driven discovery tools rather than a supplier of AI infrastructure. Recursion carries no Closelooknet score and no index seat. It appears in the Pattern 03 report, which follows NVIDIA's strategic equity stakes as an early signal for the Rubin build-out, and in the Daily Pulse that tracks the resulting cohort; the most recent Daily Pulse shows Recursion had exited that tracked portfolio. (Company snapshot of 2026-09-17.)

What has Wall Street done on Recursion Pharmaceuticals Inc recently?

The most recent analyst action on Recursion Pharmaceuticals Inc on the Closelooknet wire is a price target by Morgan Stanley on 2026-10-16 (target 5.9 from 5.3). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for RXRX, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

same Closelooknet index seat first, then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.